SCHEMBL614262

SCHEMBL614262

NC(=O)c1sc(-c2ccncc2)cc1NCc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 5/20 0.65
ROCK2 O75116 2/20 0.65
MAP4K4 O95819 2/20 0.65
GSK3B P49841 2/20 0.65
CLK4 Q9HAZ1 2/20 0.65
MKNK2 Q9HBH9 1/20 0.65
IKBKB O14920 8/20 0.62
DBF4 Q9UBU7 2/20 0.54
CDK2 P24941 2/20 0.53
PIM1 P11309 1/20 0.53
JAK2 O60674 1/20 0.52
KDM4C Q9H3R0 2/20 0.49
KDM4E B2RXH2 1/20 0.49
KDM6B O15054 1/20 0.49
KDM4A O75164 1/20 0.49
KDM4D Q6B0I6 1/20 0.49
CCNE1 P24864 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL614118 0.90 CDC7 (0.54) CDC7ROCK2MAP4K4GSK3BCLK4
SCHEMBL612007 0.86 MAPT (0.56) CDC7ROCK2MAP4K4GSK3BCLK4
SCHEMBL613690 0.82 CDC7 (0.59) CDC7ROCK2MAP4K4GSK3BCLK4
SCHEMBL5898711 0.81 JAK2 (0.68) CDC7ROCK2MAP4K4GSK3BCLK4
SCHEMBL12357351 0.80 PTPN1 (0.61) IKBKB
SCHEMBL613122 0.80 CDC7 (0.57) CDC7IKBKBDBF4CDK2JAK2
SCHEMBL27610463 0.79 PTPN1 (0.59) IKBKB
SCHEMBL614144 0.78 CDC7 (0.54) CDC7ROCK2MAP4K4GSK3BCLK4
SCHEMBL612250 0.78 IKBKB (0.70) CDC7IKBKBDBF4CDK2JAK2
SCHEMBL2157963 0.77 IKBKB (0.54) IKBKBKDM4ECYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403857-B1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2013-12-04 EP disclosed
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-16 US disclosed
EP-2403857-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2012-01-11 EP disclosed
WO-2010101302-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS CDC7, CDK7, DTYMK CDC7 1/4885ROCK2 2920/4885MAP4K4 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.